Measurement of Plasma and Intracellular Concentrations of Raltegravir

• Status: Completed
• Trial end date: 2011-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performance liquid chromatography (HPLC).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Treatments: Raltegravir Potassium

Criteria

Inclusion Criteria:

• Be of age greater than or equal to 19 years

• Have documented HIV

• Be taking RAL for at least 7 days

Exclusion Criteria:

• Any acute intercurrent illness that might interfere with the interpretation of the study